Regulatory Science in Action
Developing new tools, standards, and approaches to assess drug safety, efficacy, quality, and performance
1
Sub-Topic Paragraphs
RECENT ADVANCES IN THE SCIENCE OF DRUG DEVELOPMENT AND EVALUATION
![Spotlight on CDER Science](https://public4.pagefreezer.com:443/content/FDA/07-02-2023T12:52/https://www.fda.gov/files/styles/medium_3/public/SpotlightCDERScience_Drupal_1600x900_0.png?itok=2mXickgw)
Spotlight on CDER Science:
Respiratory Effects of Approved Opioid Products When Co-administered with Commonly Prescribed Drugs
![White text that reads "Regulatory Science Impact Story" on blue background](https://public4.pagefreezer.com:443/content/FDA/07-02-2023T12:52/https://www.fda.gov/files/styles/medium_3/public/Drugs-Img-Regulatory-Science-Research-Standard-Graphic-White-Text-Blue-Background-1600x900.png?itok=azoQshZ_)
Impact story:
Prescription drug promotion in online character space limited (CSL) communication
![CDER Conversations Drupal 1600 x 900](https://public4.pagefreezer.com:443/content/FDA/07-02-2023T12:52/https://www.fda.gov/files/styles/medium_3/public/CDERConversations_Drupal_1600x900.png?itok=_LAk8kua)
CDER Conversations:
Biosimilar User Fee Amendments Latest Implementation: BsUFA III
![What's New?](https://public4.pagefreezer.com:443/content/FDA/07-02-2023T12:52/https://www.fda.gov/files/styles/medium_3/public/CDER-whatsnew.png?itok=fZXimvZa)
What's New in Regulatory Science Winter 2022:
A newsletter featuring new developments and opportunities for stakeholders